Inimex Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
The basis for Inimex's pipeline was born a few years ago when company founders teamed up to investigate small cationic peptides as antimicrobials for the Canadian Bacterial Diseases Network. They found that some cationic peptides didn't kill bacteria, but had the ability to prevent or treat infection in animal models. The trio led a team to concentrate on a unique expression profile that activated innate response without stimulating inflammation, and that research forms the foundation of the company's current portfolio of compounds that selectively boost immunity.
You may also be interested in...
Biotechs Battle Bacteria
The rise in bacterial resistance has prompted a plethora of creative approaches to developing antibiotics. These range from finding completely novel targets to harnessing the body's own immune system to fight bacteria. And although biotechs have had the anti-bacterials space to themselves for the last few years, as more programs reach proof of concept, some Big Pharma may be showing signs of renewed interest.
Gloucester Pharmaceuticals Inc.
Two subtypes of T-cell mediated lymphomas have been very difficult to treat using the existing cytotoxic chemotherapy treatments. CTCL and peripheral T-cell lymphoma (PTCL) patients receiving chemotherapy may experience severe, dose-limiting toxicities and develop resistance to the therapy. Gloucester Pharmaceuticals Inc. is developing a treatment that potentially is more effective than chemo, the company says, and the National Institutes of Health is backing its development.
Hemobiotech Inc.
Hemobiotech Inc. was formed to commercialize HBOC technology originally developed at Texas Tech University. By modifying hemoglobin with ATP, glutathione and adenosine, the company claims it eliminates toxicity and vasoactivity. The company also has evidence that HemoTech may have the added benefit of inducing erythropoiesis.